Envestnet Asset Management
CPRX

Envestnet Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Envestnet Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.94M Buy
118,600
+55,887
+89% +$1.33M ﹤0.01% 2720
2025
Q4 		$1.46M Sell
62,713
-36,657
-37% -$817K ﹤0.01% 3052
2025
Q3 		$1.96M Sell
99,370
-2,237
-2% -$46K ﹤0.01% 2892
2025
Q2 		$2.2M Buy
101,607
+23,412
+30% +$553K ﹤0.01% 2759
2025
Q1 		$1.9M Buy
78,195
+13,800
+21% +$311K ﹤0.01% 2772
2024
Q4 		$1.34M Buy
64,395
+39,836
+162% +$856K ﹤0.01% 2958
2024
Q3 		$488K Sell
24,559
-6,919
-22% -$128K ﹤0.01% 3548
2024
Q2 		$488K Buy
31,478
+1,366
+5% +$21.3K ﹤0.01% 3472
2024
Q1 		$480K Sell
30,112
-6,603
-18% -$99.5K ﹤0.01% 3456
2023
Q4 		$617K Buy
36,715
+13,706
+60% +$187K ﹤0.01% 3210
2023
Q3 		$269K Buy
23,009
+1,120
+5% +$15K ﹤0.01% 3583
2023
Q2 		$294K Buy
21,889
+3,153
+17% +$45.4K ﹤0.01% 3499
2023
Q1 		$311K Buy
+18,736
New +$309K ﹤0.01% 3425

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Envestnet Asset Management's CPRX Position: Q1 2026 in Review

Envestnet Asset Management increased its Catalyst Pharmaceutical (CPRX) stake by 89% in Q1 2026, buying an estimated $1.33M and bringing the position to 118,600 shares worth $2.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2720.

Envestnet Asset Management first reported a position in CPRX in Q1 2023 and has held it in 13 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Envestnet Asset Management held 118,600 shares of Catalyst Pharmaceutical worth $2.94M as of Q1 2026.
  • Envestnet Asset Management bought 55,887 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.33M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Envestnet Asset Management's portfolio in Q1 2026, its #2720 holding.
  • Envestnet Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 13 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.